Data is Promising for New PAH Therapy
New England Journal of Medicine publishes data related to Actelion medication to treat PAH
The New England Journal of Medicine (NJM) published this week data related to Actelion Pharmaceutical’s SERAPHIN study for its drug macitentan (OPSUMIT), which is currently under review by the U.S. Food and Drug Administration for treatment in pulmonary arterial hypertension (PAH). The promise of additional therapies for PAH is important to people with systemic sclerosis who are at risk for developing PAH.
- Patients & Newly Diagnosed
- Healthcare Professionals